Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43843   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2006-000078-65
    Sponsor's Protocol Code Number:Rituximab
    National Competent Authority:UK - MHRA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2010-12-07
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedUK - MHRA
    A.2EudraCT number2006-000078-65
    A.3Full title of the trial
    Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
    A.3.2Name or abbreviated title of the trial where available
    Rituximab in myositis
    A.4.1Sponsor's protocol code numberRituximab
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorKarolinska University Hospital
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Mabthera
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration Ltd
    D.2.1.2Country which granted the Marketing AuthorisationSweden
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMabthera
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Adult polymyositis or adult dermatomyositis or juvenile dermatomyositis
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 8.1
    E.1.2Level LLT
    E.1.2Classification code 10036102
    E.1.2Term Polymyositis
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    AIM #1: To assess the efficacy of intravenous rituximab in a randomized, double blind, placebo-controlled, multicenter, phase II/III trial of refractory myositis in adults and children.
    E.2.2Secondary objectives of the trial
    AIM #2: To assess the determinants of treatment response and disease pathogenesis in patients receiving rituximab.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Adults with definite or probable DM or PM and pediatric patients five years of age and over with definite or probable JDM by the criteria of Bohan and Peter [33] (See Appendix C). Patients without the rash of DM will require a muscle biopsy (not necessarily done at enrollment) compatible with PM as determined by an experienced muscle pathologist. In order to be enrolled with a diagnosis of refractory PM, patients’ medical information will be reviewed and the diagnosis confirmed by a 3-member Adjudication Committee consisting of 3 Steering Committee members/Investigators. This adjudication process is necessary to exclude mimics of polymyositis including but not limited to inclusion body myositis, toxic or metabolic myopathies and adult onset muscular dystrophies.
    2. A diagnosis of JDM based on an age of onset (i.e. first symptom of myositis or the rash of dermatomyositis) < 18 years of age.
    3. Disease duration > 6 months from diagnosis of myositis.
    4. Refractory myositis as defined by the intolerance to or an inadequate response to corticosteroids plus an adequate regimen of at least one other IS agent such as azathioprine, methotrexate, IVIg, mycophenolate mofetil, cyclophosphamide, tacrolimus or cyclosporine A. The definition of intolerance is: side effects that require discontinuation of the medication or an underlying condition that precludes the further use of the medication.
    An adequate corticosteroid treatment trial is as follows:
    •Adult IIM: prednisone (or an equivalent corticosteroid) at a dose of at least 60 mg/day for one month
    •JDM: 1.0mg/kg/day prednisone for at least one month

    5.Baseline manual muscle testing which is based on a maximum MMT-8 score of 150 (see Appendix D): Subjects must have a score that is no greater than 125/150 in conjunction with 2 other abnormal core set measures; abnormal core set measures include the following:
    •Patient/Parent global VAS with a minimum value of 2.0cm on a 10cm scale
    •MD global VAS with a minimum value of 2.0cm on a 10cm scale
    •CHAQ/HAQ disability index with a minimum value of 0.25
    •Elevation of at least one of the muscle enzymes [which includes creatine kinase (CK), aldolase, lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] at a minimum level of 1.3 x the upper limit of normal.
    If more than one muscle enzyme is identified as being elevated and meeting the above guidelines then the most abnormal will be selected and this enzyme will be the target enzyme followed to evaluate disease improvement or worsening.
    •Global extramuscular disease activity score with a minimum value of 1.0cm on a 10cm VAS scale (this measure is the physician’s composite evaluation and is based on assessments of activity scores on the constitutional, cutaneous, skeletal, gastrointestinal, pulmonary and cardiac scales of the Myositis Disease Activity Assessment Tool (MDAAT) - see Appendix D
    6.If on prednisone, the dose must be stable for 4 weeks prior to the screening visit (recommend ≤ 1.0 mg/kg/day).
    7.Background therapy with at least 1 non-corticosteroid immunosuppressive agent is required at a stable dose for at least 6 weeks prior to the screening visit.
    •The IS agents include: methotrexate, azathioprine, cyclosporine, tacrolimus, cyclophosphamide or mycophenolate mofetil.
    8.If an IS agent was discontinued prior to the screening visit then there must be a:
    •4 week washout for methotrexate
    •8 week washout for any other IS agent
    9.If on plaquenil the dose should be stable for 8 weeks prior to Visit 1.
    10.If on statin agents the dose should be stable for 8 weeks prior to Visit 1.
    11.Ability of patient or parent to complete self-report questionnaires.
    12.Pediatric patients must be at least 5 years of age (core set measures are reliable down to age 5 and the immune system has reached maturity at this age so the risk of immunosuppression is lessened)
    13.Absolute neutrophil count >1000/mm3; platelets > 100,000/mm3; hemoglobin >10 gm/dl
    14. Men and women of reproductive potential must agree to use a reliable method of birth control during the 45 week duration of the trial described in the reproductive risks section of this protocol (section 4.3).
    15. Age of legal consent will follow applicable regulatory laws commensurate with the country in which clinical trial is being conducted. Children ages 12-17 or younger children who are developmentally able to sign his/her name must give assent.
    16. Patients must agree to forgo immunization with a live vaccine during the course of the study.
    17.Patients must have not consumed any creatine-containing products in the form of dietary supplements 30 days prior to the screening visit and agree not to consume any creatine products in the form of dietary supplements throughout the study duration. (Natural sources of creatine such as meats, salmon and tuna are acceptable)
    E.4Principal exclusion criteria
    1.Drug-induced myositis (myositis in patients taking medications known to induce myositis-like syndromes, including, but not limited to, statin agents, fibric acid derivatives, colchicine, and hydroxychloroquine).
    2.Use of colchicine during study participation is not allowed.
    3.Juvenile polymyositis; inclusion body myositis; cancer-associated myositis, defined as the diagnosis of myositis within 2 years of the diagnosis of cancer except basal or squamous cell skin cancer or carcinoma in situ of the cervix if at least 5 years since excision
    4.Myositis in overlap with another connective tissue disease (CTD) that precludes the accurate assessment of a treatment response (the 3-member committee discussed under Inclusion Criteria #1 above will also determine the eligibility of such patients with myositis and an associated CTD).
    5.History of receiving a live vaccine 4 weeks prior to initiation of study treatment
    6.Joint disease or other musculoskeletal condition, which precludes the ability to quantitate muscle strength.
    7.Known hypersensitivity to murine proteins.
    8.Concomitant illness that would prevent adequate patient assessment or pose an added risk for study participants:
    •recurrent or chronic infections, including HIV, hepatitis B and C
    •known liver disease (i.e. cirrhosis or other conditions compromising the synthetic function of the liver)
    •disorders that would preclude accurate assessment of neuromuscular function
    •cardiomyopathy/congestive heart failure/arrhythmia (or New York Heart Classification III or IV disease)
    •psychiatric illness that precludes compliance or neuromuscular assessment
    •serum creatinine > 2.0mg/dl
    •IgG or IgM levels at baseline that are below the normal range (for pediatrics age adjusted normal ranges will be followed)
    9.Pregnant females or nursing mothers
    10.Life threatening non-myositis illness that would interfere with the patient’s ability to complete the study.
    11.Known or suspected history of drug or alcohol abuse within the past 6 months as determined by the medical record or patient interview
    12.Anticipated poor compliance
    13.Participation in another clinical (experimental) study within 30 days of screening visit.
    14.Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator unsuitable for the study.
    15.Any history of receiving rituximab
    16.Evidence of prior infection of Hepatitis B and Hepatitis C
    17.Initiation of an exercise program within 4 weeks of screening visit or initiation of an exercise program during the study (See section 5.4 Other Restrictions)
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint of this trial is to compare the time to achieve the definition of improvement (DOI) between the two groups of rituximab-treated patients.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety No
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Information not present in EudraCT
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA5
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months10
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2010-12-07. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Young children, from five years of age.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 20
    F.4.2.2In the whole clinical trial 202
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    A re-treatment arm will allow for further documentation of safety and adverse events and documentation of long-term efficacy. Therefore patients, who meet the definition of improvement during the trial (defined in Appendix D1) and then meet the criteria for worsening (defined in Appendix F) by week 36, will be offered retreatment with rituximab.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2008-12-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2008-05-19
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2009-09-01
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 18 02:18:24 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA